KANG-HSI WU2026-10-162026-10-162006-07-01Pure ID: 15033802Pure UUID: 78d6a036-a658-4690-82ab-3c737d13f42610.1080/03630260600642609https://www.scopus.com/pages/publications/33745533131https://scholars.csmu.edu.tw/handle/123456789/23552While hypertransfusion and subcutaneous iron chelation therapy have increased longevity of patients with β-thalassemia (thal) major, endocrinopathies have become more common and impair the quality of their lives. Additionally, subcutaneous iron chelation therapy is an uncomfortable experience and can prevent patients from regular compliance with iron chelation therapy. We compared the efficacy of oral deferiprone (L1) to subcutaneous desferrioxamine (DFO) chelation therapy for the prevention of major endocrinopathies (growth hormone insufficiency, diabetes mellitus and gonadal dysfunction) among patients with β-thal major to see if we could offer these patients an easier and more painless way to reduce their body iron load and related endocrine complications.6enjournal article